Policy On Disclosure Of Information By Third Parties
On occasion Prometic Life Sciences Inc. (“Prometic”) forwards general information of interest and relating to its various fields of activities such as blood, blood safety, vCJD, and anemia, as well as the use of its proprietary products within the healthcare industry. This service is provided to our shareholders as a means to inform them on the landscape in which Prometic is evolving. From time to time, Prometic will provide information to third parties as part of interviews or due diligence, with such information that can be incorporated in articles or research reports. As part of its policy, Prometic does not post such articles or research reports as Prometic cannot guarantee the accuracy or reliability for the subsequent distribution of this information by third parties (see full disclosure on the Legal Disclaimer page).
- Where is Prometic s corporate headquarters?
Prometic’s corporate headquarters is located at 440 Armand Frappier Boulevard in Laval, Quebec, Canada. We also have operations and employees based throughout Canada, the United States and the UK.
- Who are the members of Prometic s Board of Directors?
You can view the Corporation’s Board of Directors by visiting the Board of Directors page on the website.
- Who are the members of the Prometic management team?
You can view the Corporation’s management team by visiting the Management page on the website.
- How do I contact Investor Relations with a question or request?
You can submit questions to the Prometic investor relations team by contacting email@example.com or by submitting a request via the Contact Us page.
- When is Prometic s fiscal year end?
The Corporation’s fiscal year end is December 31.
- When Are Prometic’s Earnings Reporting Dates?
- First Quarter Earnings – by or on May 15, 2018
- Second Quarter Earnings – by or on August 14, 2018
- Third Quarter Earnings – by or on November 14, 2018
- Year End / Annual Report – by or on March 31, 2019
- When And Where Is Prometic’s Annual Meeting Of Shareholders?
The last Annual and Special Meeting of Shareholders was on:
Wednesday, May 9, 2018 at 10:30 (EDT)
Fairmont The Queen Elizabeth, Room Agora
900 Rene Levesque Blvd. W., Montreal, Québec
The next Annual Meeting of Shareholders will be held in May 2019, in Montreal.
- How Do I Get Copies Of Prometic’s Financial Documents?
These may be downloaded from Prometic’s web site at http://prometic.com/en/investors/financial-reports.php
- How many common shares are currently issued and outstanding on a fully diluted basis?
Update available on the www.TSX.com website.
As of April 30, 2019, the Corporation had 20,947,510,578 common shares issued and outstanding on a fully-diluted basis, including all outstanding warrants, stock options and restricted share units.
- Does Prometic Issue Dividends?
Not as of yet.
- Who Is Prometic’s Transfer Agent?
Our transfer agent is Computershare. You can contact Computershare via their website at: www.computershare.com.
Written requests by regular mail can be made to:
Computershare Investor Services
P.O. Box 43078
Providence, RI 02940-3078 USA
Computershare Investor Services
100 University Avenue, 8th Floor, North Tower
Toronto, Ontario M5J 2Y1 Canada
Telephone enquiries at 1-800-564-6253 (toll free in Canada and the USA) between the hours of 8:30 am and 8:00 pm Eastern Time or 514-982-7555 (international direct dial).
- Who are the Corporation’s auditors?
The Corporation’s auditors are currently Ernst & Young. Shareholders will be requested to appoint Price Waterhouse Coopers as our auditors at the upcoming Annual and Special Meeting of Shareholders on June 19, 2019
- Latest Regulatory Filings
To view Prometic Life Sciences Inc.’s filed regulatory documents, visit the Canadian Securities Administrators’ SEDAR® website www.sedar.com*
- Insider Trading Reports
To view all electronic insider trading reports, visit the Canadian Securities Administrators’ SEDI website www.sedi.ca *
*These links will take you to an independent third party website site.
Lennox Gibbs, TD Securities, Tel.: (416) 308-2213
Endri Leno, National Bank, Tel.: (416) 869-8047
Doug Loe, Ph.D, MBA, Echelon Partners, Tel.: (416) 775-1004
Doug Miehm, RBC, Tel.: (416) 842-7823
Derren Nathan, Hybridan LLP, Tel.: 44 (0) 20 7313 4584
Rahul Sarugaser, Paradigm Capital, Tel: (416) 216-3564
DISCLAIMER – Issued by the Directors and Management of Prometic Life Sciences Inc. (“The Company”)
Research analysts have from time to time published material commenting on The Company. Any opinions, estimates or forecasts regarding The Company’s performance made by such analysts are theirs alone and do not represent opinions, forecasts or predictions of The Company or its Management. By distributing the information below The Company does not imply its endorsement of or concurrence with such information. The Company does not accept any responsibility whatsoever for the views of these or any other analysts reporting on The Company.
- Investor Information
Prometic Life Sciences Inc.
440 Boul. Armand-Frappier, Suite 300
Laval, Quebec H7V 4B4
Only public information or information which could otherwise be disclosed in accordance with Prometic’s Corporate Communication and Disclosure Policy shall be utilized in responding to inquiries. Please provide your telephone number so that we may contact you.
- On what exchanges are the Corporation’s shares listed for trading and what is the ticker symbol
The common shares of Prometic are listed on The Toronto Stock Exchange under the stock symbol PLI.
Toronto Stock Exchange
- Annual Information Form
The 2017 Annual Information Form of Prometic Life Sciences Inc. is available upon request from the Company’s Head Office or by accessing the SEDAR (System for Electronic Document Analysis and Retrieval) site, www.sedar.com.
- What happens to my shares when the Corporation completes the proposed reverse share consolidation?
The Corporation will be requesting approval from shareholders at the upcoming Annual and Special Meeting of the Shareholders, to be held on June 19th 2019, to amend its articles to effect a consolidation of all of its issued and outstanding common shares (the “Common Shares”), on the basis of a consolidation ratio to be selected by the Board within a range between seven hundred fifty (750) pre-consolidation Common Shares for one (1) post-consolidation Common Share and one thousand two hundred fifty (1250) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the “Share Consolidation”), effective as at the discretion of the Board . Prometic intends to proceed with such share consolidation in a timely fashion after receipt of the necessary shareholder and other approvals.
If the Share Consolidation would otherwise result in a person with an interest in Common Shares being entitled to post-consolidation Common Share(s) and to fractional post-consolidation Common Share(s), the Corporation intends, pursuant to the Share Resolution:
(i) in the event that a shareholder would be entitled to receive a fractional Common Share after the Consolidation that is equivalent to less than 75% of a whole post-consolidation Common Share, the Corporation intends, pursuant to the Share Resolution, for the Corporation to buy the fraction and send payment to the holder (except for amounts of C$5 or less, which shall be retained for the benefit of the Corporation). The price to be paid for a fraction will be based on the Average Closing Price and shall result in payment for each whole pre-consolidation Common Share held prior to the Share Consolidation (other than the pre-consolidation Common Shares consolidated into post-consolidation Common Shares) which together constitute the fraction; or
(ii) in the event that a shareholder would be entitled to receive a fractional Common Share after the Consolidation that is equivalent to 75% or more of a whole post-consolidation Common Share, the Corporation intends, pursuant to the Share Resolution, for the Corporation to round up to one whole Common Share.
- Who is Structured Alpha LP?
Structured Alpha LP, of which Thomvest Asset Management, an investment firm based in Toronto, Canada is the sole general partner, is a limited partnership which invests in debt and equity securities of public and private emerging growth companies. Structured Alpha LP is our largest shareholder as of April 30, 2019.
- What amount of the outstanding debt owed to Structured Alpha was converted into equity?
In April 2019, Prometic entered into a debt restructuring agreement (the “Restructuring Agreement”) with Structured Alpha. Under the terms of the Restructuring Agreement, Prometic’s outstanding indebtedness to Structured Alpha was reduced to $10 million by way of conversion of approximately $229 million of outstanding indebtedness (debt and interest) into common shares, at a conversion price per common share equal to the $0.01521 (rounded to five decimal places). This transaction and a concurrent equity financing were reviewed and approved by The Toronto Stock Exchange. Further information on this transaction can be found in the press release dated April 16, 2019 included in our Press Releases section of the Investors webpage.
- Where can I find more information on the Prometic’s Corporation Rights Offering?
More details on the Rights Offering will be set out in Prometic’s Rights Offering notice and Rights Offering circular, both of which are available under Prometic’s SEDAR profile at www.sedar.com and on our website under Investor Briefcase. The Rights Offering notice and accompanying rights certificates have been mailed to eligible shareholders on May 24, 2019.